Treatment of hematological cancer with PD-1/CD3 bispecific protein

The purpose of the present invention is to provide a novel drug useful in prophylaxis, syndrome progressing inhibition, recurrence inhibition or treatment to blood cancers. The inventors of the present invention have conducted intense studies, and as a result, focuses on a bispecific protein (prefer...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	SHIMBO, TAKUYA, SHIBAYAMA, SHIRO
Format:	Patent
Sprache:	chi ; eng
Schlagworte:	BEER BIOCHEMISTRY CHEMISTRY COMPOSITIONS THEREOF CULTURE MEDIA ENZYMOLOGY HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY MICROBIOLOGY MICROORGANISMS OR ENZYMES MUTATION OR GENETIC ENGINEERING ORGANIC CHEMISTRY PEPTIDES PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS SPIRITS VINEGAR WINE
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The purpose of the present invention is to provide a novel drug useful in prophylaxis, syndrome progressing inhibition, recurrence inhibition or treatment to blood cancers. The inventors of the present invention have conducted intense studies, and as a result, focuses on a bispecific protein (preferably PD-1/CD3 bispecific antibody or fragments thereof) having a first arm which is specific binding to PD-1 and a second arm which is specific binding to CD3 as a substance able to solve the above issues, and found that the bispecific protein is useful in prophylaxis, syndrome progressing inhibition, recurrence inhibition or treatment to blood cancers.